Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6312 | KML 29 |
| Highly selective and potent monoacylglycerol lipase (MAGL) inhibitor. Exhibits potent inhibition of human, mouse and rat MAGL (IC50 values are 5.9, 15 and 43 nM, respectively). Exhibits no detectable inhibition of FAAH (IC50 > 50000 nM). Potently and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50 = 2.5 nM and >50 μM for 2-AG and AEA respectively). | |
| BCC6313 | Eact |
| TMEM16A (ANO1) calcium-activated chloride channel (CaCC) activator (EC50 = 3 μM). Ca2+-independent. Displays no effect on CFTR Cl- or ENaC Na+ conductance. Stimulates submucosal gland secretion in human bronchi. | |
| BCC6314 | CaCCinh-A01 |
| Calcium-activated chloride channel (CaCC) inhibitor (IC50 ~ 10 μM). Inhibits CaCC currents in human bronchial and intestinal cells. Also inhibits TMEM16A channels (IC50 = 2.1 μM, in TMEM16A-expressing FRT cells). | |
| BCC6316 | TC-G 1001 |
| GPR35 agonist (pEC50 values are 7.59 and 8.36 for β-arrestin and Gαq-i5 Ca2+ assays respectively). Displays 1000-fold greater potency at human GPR35 receptors relative to mouse and rat GPR35 orthologs in an IP1 accumulation assay. More potent than zaprinast. | |
| BCC6318 | LUF 6283 |
| Partial agonist of hydroxycarboxylic acid receptor 2 (HCA2) (Ki = 0.55 μM). Thought to lower plasma very-low-density lipoprotein (VLDL)-triglyceride levels by affecting hepatic VLDL production in normolipidemic C57BL/6 mice. | |
| BCC6319 | CU CPT 4a |
| Selective TLR3 inhibitor (IC50 = 3.44 μM in RAW 264.7 cells); suppresses downstream signaling pathways mediated by the TLR3/dsRNA complex, inhibiting TNF-α and IL-1β production in whole cells. | |
| BCC6320 | CU CPT 22 |
| Selective toll-like receptor 1/2 (TLR1/2) inhibitor (IC50 = 0.58 μM). Exhibits no activity at TLR2/TLR6, TLR3, TLR4 and TLR7 or a panel of 10 representative kinases. Inhibits the release of proinflammatory cytokines TNF-α and IL-1β. | |
| BCC6321 | CYM 5541 |
| Selective sphingosine-1-phosphate receptor 3 (S1P3) allosteric agonist (EC50 = 72-132 nM). Occupies a different space within the ligand binding pocket of S1P3 than S1P. Displays no activity at S1P1, S1P2, S1P4 and S1P5 receptors at concentrations up to 10 μM. Shows no significant activities in a profiling panel of 55 GPCRs, ion channels and transporters. | |
